[5] Access may vary depending on state and current supply
Withdrawal of semaglutide led to weight regain, highlighting the chronic nature of obesity and the need for long-term treatment strategies (Rubino, Diabetes, Obesity and Metabolism )
Note that most side effects decrease as your body adjusts to treatment, and the benefits usually outweigh these temporary challenges
Jain, S., Kaur, J., Prasad, S
Even though GLP-1 receptor agonists are exciting, Pedersen hopes to one day see additional new classes of drugs so that we can help those patients who just dont tolerate the GLP-1. Options Grow despite Short Supplies Companies are rapidly working on the next improved GLP-1 receptor agonist